Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the peer-reviewed publication of preclinical results of its COVID-19 vaccine candidate, MRT5500, in the journal npj Vaccines. Preclinical evaluation of MRT5500 demonstrated a favorable immune response profile against SARS-CoV-2 and conferred protective efficacy against the disease in an infection challenge model. The full journal article is available here. MRT5500 is being developed under a collaboration agreement between Sanofi Pasteur and Translate Bio. The Phase 1/2 clinical trial of MRT5500 began in March 2021 and clinical data is anticipated in the third quarter of this year.
Frank DeRosa, PhD, chief technology officer at Translate Bio and an author of the publication said, “These preclinical results demonstrated the ability of MRT5500 to elicit a robust immune response and protection against COVID-19 in multiple species through a highly rigorous set of studies. This growing body of preclinical data for MRT5500, as well as the new variant mRNA constructs that we are testing, support the potential for our mRNA vaccine candidates to play a role in protecting people against COVID-19. We look forward to seeing the results from the ongoing first-in-human trial.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.